-
Je něco špatně v tomto záznamu ?
The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model
K. Štefková-Mazochová, H. Danda, V. Mazoch, L. Olejníková-Ladislavová, K. Šíchová, N. Paškanová, M. Vágnerová, B. Jurásek, P. Ryšánek, M. Šíma, A. Šafanda, QH. Bui, M. Kuchař, T. Páleníček
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- chování zvířat účinky léků MeSH
- krysa rodu rattus MeSH
- LD50 MeSH
- mozek účinky léků metabolismus MeSH
- piperidiny farmakokinetika farmakologie MeSH
- pohybová aktivita účinky léků MeSH
- potkani Wistar * MeSH
- prepulsní inhibice účinky léků MeSH
- test otevřeného pole účinky léků MeSH
- vztah mezi dávkou a účinkem léčiva * MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration: pharmacokinetics in the brain and serum; behaviour (open field and prepulse inhibition), systemic toxicity (lethal dose; LD 50), and histopathology changes in parenchymal organs of Wistar rats. MXP rapidly crossed the blood-brain barrier, reaching peak median concentrations in both serum and brain 30 min post-administration, followed by an elimination phase with a half-life of 2.15 h. Locomotor activity in the open field test displayed a dose-response effect at low to moderate doses (10-20 mg/kg MXP). At higher doses (40 mg/kg), locomotor activity decreased. All doses of MXP significantly disrupted prepulse inhibition and the effect was present during the onset of its action as well as 60 min after treatment. Additionally, MXP demonstrated moderate acute toxicity, with an estimated LD50 of 500 mg/kg when administered subcutaneously. In summary, MXP exhibited a profile similar to typical dissociative anesthetics, producing stimulant and anxiogenic effects at lower doses, sedative effects at higher doses, and disrupting sensorimotor gating. The accumulation of MXP in brain tissue is likely to contribute to acute intoxication in humans, potentially leading to negative experiences. Our findings highlight the potentially dangerous effects of recreational MXP use and underscore the risks of inducing serious adverse health outcomes.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009462
- 003
- CZ-PrNML
- 005
- 20250429134816.0
- 007
- ta
- 008
- 250415e20250208enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pnpbp.2025.111285 $2 doi
- 035 __
- $a (PubMed)39929370
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Štefková-Mazochová, Kristýna $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic. Electronic address: kristyna.mazochova@nudz.cz
- 245 14
- $a The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model / $c K. Štefková-Mazochová, H. Danda, V. Mazoch, L. Olejníková-Ladislavová, K. Šíchová, N. Paškanová, M. Vágnerová, B. Jurásek, P. Ryšánek, M. Šíma, A. Šafanda, QH. Bui, M. Kuchař, T. Páleníček
- 520 9_
- $a Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration: pharmacokinetics in the brain and serum; behaviour (open field and prepulse inhibition), systemic toxicity (lethal dose; LD 50), and histopathology changes in parenchymal organs of Wistar rats. MXP rapidly crossed the blood-brain barrier, reaching peak median concentrations in both serum and brain 30 min post-administration, followed by an elimination phase with a half-life of 2.15 h. Locomotor activity in the open field test displayed a dose-response effect at low to moderate doses (10-20 mg/kg MXP). At higher doses (40 mg/kg), locomotor activity decreased. All doses of MXP significantly disrupted prepulse inhibition and the effect was present during the onset of its action as well as 60 min after treatment. Additionally, MXP demonstrated moderate acute toxicity, with an estimated LD50 of 500 mg/kg when administered subcutaneously. In summary, MXP exhibited a profile similar to typical dissociative anesthetics, producing stimulant and anxiogenic effects at lower doses, sedative effects at higher doses, and disrupting sensorimotor gating. The accumulation of MXP in brain tissue is likely to contribute to acute intoxication in humans, potentially leading to negative experiences. Our findings highlight the potentially dangerous effects of recreational MXP use and underscore the risks of inducing serious adverse health outcomes.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a potkani Wistar $7 D017208
- 650 12
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a pohybová aktivita $x účinky léků $7 D009043
- 650 _2
- $a prepulsní inhibice $x účinky léků $7 D065808
- 650 _2
- $a mozek $x účinky léků $x metabolismus $7 D001921
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a piperidiny $x farmakokinetika $x farmakologie $7 D010880
- 650 _2
- $a LD50 $7 D007928
- 650 _2
- $a chování zvířat $x účinky léků $7 D001522
- 650 _2
- $a test otevřeného pole $x účinky léků $7 D000082563
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Danda, Hynek $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic; 3(rd) Faculty of Medicine, Charles University, Ruská 87, Prague 10 100 00, Czech Republic
- 700 1_
- $a Mazoch, Vladimír $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic
- 700 1_
- $a Olejníková-Ladislavová, Lucie $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic
- 700 1_
- $a Šíchová, Klára $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic
- 700 1_
- $a Paškanová, Natálie $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic
- 700 1_
- $a Vágnerová, Magdaléna $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic; Department of Analytical Chemistry, University of Chemistry and Technology, Technická 5, Prague 6 166 28, Czech Republic
- 700 1_
- $a Jurásek, Bronislav $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic
- 700 1_
- $a Ryšánek, Pavel $u Institute of Pharmacology, 1(st) Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, Prague 2 128 00, Czech Republic
- 700 1_
- $a Šíma, Martin $u Institute of Pharmacology, 1(st) Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, Prague 2 128 00, Czech Republic
- 700 1_
- $a Šafanda, Adam $u Institute of Pathology, 1(st) Faculty of Medicine, Charles University, Studničkova 2, Prague 2 128 00, Czech Republic
- 700 1_
- $a Bui, Quang Hiep $u Institute of Pathology, 1(st) Faculty of Medicine, Charles University, Studničkova 2, Prague 2 128 00, Czech Republic
- 700 1_
- $a Kuchař, Martin $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic; Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technická 5, Prague, 6, 166 28, Czech Republic
- 700 1_
- $a Páleníček, Tomáš $u Psychedelics Research Centre, National Institute of Mental Health, Topolová 748, Klecany 250 67, Czech Republic; 3(rd) Faculty of Medicine, Charles University, Ruská 87, Prague 10 100 00, Czech Republic. Electronic address: tomas.palenicek@nudz.cz
- 773 0_
- $w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 137 (20250208), s. 111285
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39929370 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134812 $b ABA008
- 999 __
- $a ok $b bmc $g 2311068 $s 1246543
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 137 $c - $d 111285 $e 20250208 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
- LZP __
- $a Pubmed-20250415